-
-
-
-
-
-
-
AstraZeneca forecasts 2026 sales, profit growth as Q4 meets expectations; stock up
-
-
-
-
-
-
-
AstraZeneca's 9M and Q3 2025 Financial Results
-
-
-
-
-
-
-
AstraZeneca seeks US drug price cuts amid expansion plans, strong demand
-
-
-
-
-
-
-
These 5 stocks are latest additions to Goldman's 'European Conviction List - Directors’ Cut' list
-
-
-
-
-
-
-
AstraZeneca (AZN) Tops Q4 EPS by 103c; offers guidance
-
-
-
-
-
-
-
AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States
-
-
-
-
-
-
-
AstraZeneca raises profit outlook on strong medicines demand
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

